BACKGROUND:Mild to moderate depressive symptoms are common but often remain unrecognized and treated inadequately. We hypothesized that an Internet intervention in addition to usual care is superior to care as usual alone (CAU) in the treatment of mild to moderate depressive symptoms in adults. METHODS: This trial was controlled, randomized and assessor-blinded. Participants with mild to moderate depressive symptoms (Patient Health Questionnaire, PHQ-9, score 5-14) were recruited from clinical and non-clinical settings and randomized to either CAU or a 12-week Internet intervention (Deprexis) adjunctive to usual care. Outcomes were assessed at baseline, 3 months (post-assessment) and 6 months (follow-up). The primary outcome measure was self-rated depression severity (PHQ-9). The main analysis was based on the intention-to-treat principle and used linear mixed models. RESULTS: A total of 1,013 participants were randomized. Changes in PHQ-9 from baseline differed signixFB01;cantly between groups (t825 = 6.12, p < 0.001 for the main effect of group). The post-assessment between-group effect size in favour of the intervention was d = 0.39 (95% CI: 0.13-0.64). It was stable at follow-up, with d = 0.32 (95% CI: 0.06-0.69). The rate of participants experiencing at least minimally clinically important PHQ-9 change at the post-assessment was higher in the intervention group (35.6 vs. 20.2%) with a number needed to treat of 7 (95% CI: 5-10). CONCLUSIONS: The Internet intervention examined in this trial was superior to CAU alone in reducing mild to moderate depressive symptoms. The magnitude of the effect is clinically important and has public health implications.
RCT Entities:
BACKGROUND: Mild to moderate depressive symptoms are common but often remain unrecognized and treated inadequately. We hypothesized that an Internet intervention in addition to usual care is superior to care as usual alone (CAU) in the treatment of mild to moderate depressive symptoms in adults. METHODS: This trial was controlled, randomized and assessor-blinded. Participants with mild to moderate depressive symptoms (Patient Health Questionnaire, PHQ-9, score 5-14) were recruited from clinical and non-clinical settings and randomized to either CAU or a 12-week Internet intervention (Deprexis) adjunctive to usual care. Outcomes were assessed at baseline, 3 months (post-assessment) and 6 months (follow-up). The primary outcome measure was self-rated depression severity (PHQ-9). The main analysis was based on the intention-to-treat principle and used linear mixed models. RESULTS: A total of 1,013 participants were randomized. Changes in PHQ-9 from baseline differed signixFB01;cantly between groups (t825 = 6.12, p < 0.001 for the main effect of group). The post-assessment between-group effect size in favour of the intervention was d = 0.39 (95% CI: 0.13-0.64). It was stable at follow-up, with d = 0.32 (95% CI: 0.06-0.69). The rate of participants experiencing at least minimally clinically important PHQ-9 change at the post-assessment was higher in the intervention group (35.6 vs. 20.2%) with a number needed to treat of 7 (95% CI: 5-10). CONCLUSIONS: The Internet intervention examined in this trial was superior to CAU alone in reducing mild to moderate depressive symptoms. The magnitude of the effect is clinically important and has public health implications.
Authors: E Karyotaki; A Kleiboer; F Smit; D T Turner; A M Pastor; G Andersson; T Berger; C Botella; J M Breton; P Carlbring; H Christensen; E de Graaf; K Griffiths; T Donker; L Farrer; M J H Huibers; J Lenndin; A Mackinnon; B Meyer; S Moritz; H Riper; V Spek; K Vernmark; P Cuijpers Journal: Psychol Med Date: 2015-04-17 Impact factor: 7.723
Authors: Jay C Fournier; Robert J DeRubeis; Steven D Hollon; Sona Dimidjian; Jay D Amsterdam; Richard C Shelton; Jan Fawcett Journal: JAMA Date: 2010-01-06 Impact factor: 56.272
Authors: Gerhard Andersson; Björn Paxling; Pie Roch-Norlund; Gunnar Östman; Anna Norgren; Jonas Almlöv; Lisa Georén; Elisabeth Breitholtz; Mats Dahlin; Pim Cuijpers; Per Carlbring; Farrell Silverberg Journal: Psychother Psychosom Date: 2012-09-06 Impact factor: 17.659
Authors: Jan Philipp Klein; Thomas Berger; Johanna Schröder; Christina Späth; Björn Meyer; Franz Caspar; Wolfgang Lutz; Wolfgang Greiner; Martin Hautzinger; Matthias Rose; Viola Gräfe; Fritz Hohagen; Gerhard Andersson; Eik Vettorazzi; Steffen Moritz Journal: BMC Psychiatry Date: 2013-09-28 Impact factor: 3.630
Authors: Simon Gilbody; Elizabeth Littlewood; Catherine Hewitt; Gwen Brierley; Puvan Tharmanathan; Ricardo Araya; Michael Barkham; Peter Bower; Cindy Cooper; Linda Gask; David Kessler; Helen Lester; Karina Lovell; Glenys Parry; David A Richards; Phil Andersen; Sally Brabyn; Sarah Knowles; Charles Shepherd; Debbie Tallon; David White Journal: BMJ Date: 2015-11-11
Authors: Marit Knapstad; Linn Vathne Lervik; Solbjørg Makalani Myrtveit Sæther; Leif Edvard Aarø; Otto Robert F Smith Journal: Psychother Psychosom Date: 2019-12-03 Impact factor: 17.659
Authors: Björn Meyer; Mario Weiss; Martin Holtkamp; Stephan Arnold; Katja Brückner; Johanna Schröder; Franziska Scheibe; Yvonne Nestoriuc Journal: BMC Psychiatry Date: 2017-02-07 Impact factor: 3.630
Authors: Rüdiger Zwerenz; Jan Becker; Robert Johansson; Ronald J Frederick; Gerhard Andersson; Manfred E Beutel Journal: JMIR Ment Health Date: 2017-10-16
Authors: Jan Philipp Klein; Carla Gamon; Christina Späth; Thomas Berger; Björn Meyer; Fritz Hohagen; Martin Hautzinger; Wolfgang Lutz; Eik Vettorazzi; Steffen Moritz; Johanna Schröder Journal: BMJ Open Date: 2017-07-13 Impact factor: 2.692
Authors: Till Beiwinkel; Tabea Eißing; Nils-Torge Telle; Elisabeth Siegmund-Schultze; Wulf Rössler Journal: J Med Internet Res Date: 2017-06-15 Impact factor: 5.428
Authors: Wolfgang Lutz; Alice Arndt; Julian Rubel; Thomas Berger; Johanna Schröder; Christina Späth; Björn Meyer; Wolfgang Greiner; Viola Gräfe; Martin Hautzinger; Kristina Fuhr; Matthias Rose; Sandra Nolte; Bernd Löwe; Fritz Hohagen; Jan Philipp Klein; Steffen Moritz Journal: J Med Internet Res Date: 2017-06-09 Impact factor: 5.428
Authors: Eirini Karyotaki; Orestis Efthimiou; Clara Miguel; Frederic Maas Genannt Bermpohl; Toshi A Furukawa; Pim Cuijpers; Heleen Riper; Vikram Patel; Adriana Mira; Alan W Gemmil; Albert S Yeung; Alfred Lange; Alishia D Williams; Andrew Mackinnon; Anna Geraedts; Annemieke van Straten; Björn Meyer; Cecilia Björkelund; Christine Knaevelsrud; Christopher G Beevers; Cristina Botella; Daniel R Strunk; David C Mohr; David D Ebert; David Kessler; Derek Richards; Elizabeth Littlewood; Erik Forsell; Fan Feng; Fang Wang; Gerhard Andersson; Heather Hadjistavropoulos; Heleen Christensen; Iony D Ezawa; Isabella Choi; Isabelle M Rosso; Jan Philipp Klein; Jason Shumake; Javier Garcia-Campayo; Jeannette Milgrom; Jessica Smith; Jesus Montero-Marin; Jill M Newby; Juana Bretón-López; Justine Schneider; Kristofer Vernmark; Lara Bücker; Lisa B Sheeber; Lisanne Warmerdam; Louise Farrer; Manuel Heinrich; Marcus J H Huibers; Marie Kivi; Martin Kraepelien; Nicholas R Forand; Nicky Pugh; Nils Lindefors; Ove Lintvedt; Pavle Zagorscak; Per Carlbring; Rachel Phillips; Robert Johansson; Ronald C Kessler; Sally Brabyn; Sarah Perini; Scott L Rauch; Simon Gilbody; Steffen Moritz; Thomas Berger; Victor Pop; Viktor Kaldo; Viola Spek; Yvonne Forsell Journal: JAMA Psychiatry Date: 2021-04-01 Impact factor: 21.596